Long-term 1-carnitine treatment prolongs the survival in rats with adriamycin-induced heart failure

Journal of Cardiac Failure

Volumn 2, Issue 4, 1996, Pages 293-299

  Kawasaki, Norio ^a   Lee, Jong Dae ^a   Shimizu, Hiromasa ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Carnitine; Heart failure; High energy phosphate; Survival

Indexed keywords

ACYL COENZYME A; ADENOSINE TRIPHOSPHATE; CARNITINE; CREATINE PHOSPHATE; DOXORUBICIN;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CONGESTIVE HEART FAILURE; CULTURE TECHNIQUE; DISEASE MODEL; DRUG ADMINISTRATION; HEART MUSCLE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; SURVIVAL RATE;

ACYL COENZYME A; ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CARNITINE; CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE, CONGESTIVE; MALE; MYOCARDIUM; PHOSPHOCREATINE; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE;

EID: 0030346365     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(96)80016-9     Document Type: Article

References (13)

1. Neely, JR, Morgan HE: Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 1974;36:413-59
2. Saddik M, Lopaschuk GD: Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 1991;266:8162-70
3. Opie LH: Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Hear J 1979;97:375-88
4. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure: experimental and clinical study. Jpn Circ J 1992;56:86-94
5. Pierpont MEM, Judd D, Goldenberg IF, Ring WS, Olivari MT, Pierpont GL: Myocardial carnitine in end-stage congestive heart failure. Am J Cardiol 1989;64:56-60
6. Regitz V, Shug AL, Fleck E: Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 1990;65: 755-60
7. Masumura Y, Kobayashi A, Yamazaki N: Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J 1990;54:1471-6
8. Kawasaki N, Lee J-D, Shimizu H, Ishii Y, Ueda T: Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats. Int J Cardiol 1996;55:217-25
9. Broderick TL, Quinney HA, Barker CC, Lopaschuk GD: Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993;87:972-81
10. Yamashita T, Kobayashi A, Yamzaki N, Miura K, Shirasawa H: Effects of L-carnitine and verapamil on myocardial carnitine concentration and histopathology of Syrian hamster. BIO 14.6. Cardiovasc Res 1986;20:614-20
11. Whitner JT: L-carnitine treatment improves cardiac performance and restores high-energy phosphate pools in cardiomyopahtic Syrian hamster. Circ Res 1987;61:396-408
12. McFalls EO, Paulson DJ, Gilbert EF, Shug AL: Carnitine protection against adriamycin-induced cardiomyopathy in rats. Life Sci 1986;38:497-505
13. Pierpont MEM, Foker JE, Pierpont GL: Myocardial carnitine metabolism in congestive heart failure induced by incessant tachycardia. Basic Res Cardiol 1993;88:362-70